See the DrugPatentWatch profile for Esperoct
Esperoct, also known by its generic name turoctocog alfa, is a recombinant protein that functions as a coagulation factor. It is a long-acting form of coagulation factor VIII, designed to treat hemophilia A [1].
How does Esperoct work for hemophilia A?
Esperoct is a modified version of coagulation factor VIII, a protein that is deficient or defective in individuals with hemophilia A [2]. By replacing or supplementing the missing factor VIII, Esperoct helps to restore the blood's ability to clot, thereby preventing or controlling bleeding episodes [1]. The modification to the protein extends its half-life in the body, allowing for less frequent dosing compared to standard factor VIII therapies [3].
What is the difference between turoctocog alfa and other factor VIII treatments?
Turoctocog alfa, the active ingredient in Esperoct, is engineered for a longer duration of action [3]. Standard factor VIII treatments require more frequent administration to maintain adequate levels in the bloodstream. Esperoct's extended half-life allows for less frequent prophylactic treatment, potentially improving convenience and adherence for patients [1][4].
When does patent exclusivity expire for Esperoct?
Patent exclusivity timelines for drugs can be complex and vary by region. Information on specific patent expiry dates for Esperoct can be found on specialized databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which may include details on Esperoct [5].
What are the risks or side effects associated with Esperoct?
Like other factor VIII products, Esperoct carries risks, including the potential for allergic reactions and the development of inhibitors, which are antibodies that can neutralize the therapeutic effect of factor VIII [1][2]. Common side effects may include injection site reactions [1]. Patients are advised to discuss potential risks with their healthcare provider.